Factors Affecting Treatment and Prognosis in Thymomas: A Multi-Center Experience

Basit Öğe Kaydı
dc.authoridKaraman, Sule/0000-0002-4810-4453
dc.authoridTepetam, Huseyın/0000-0002-6571-4114
dc.authoridGurocak, Asc Prof Simay/0000-0002-3707-5183
dc.authoridAltınok, Pelin/0000-0001-5970-6452
dc.authorwosidKaraman, Sule/AAS-5135-2020
dc.authorwosidTepetam, Huseyın/JCP-0050-2023
dc.authorwosidGurocak, Asc Prof Simay/N-3351-2014
dc.authorwosidKirakli, Esra Korkmaz/T-9073-2018
dc.authorwosidAltınok, Pelin/AAR-9359-2020
dc.contributor.authorKarabulut Gul, Sule
dc.contributor.authorTepetam, Huseyin
dc.contributor.authorKaraman, Sule
dc.contributor.authorGurocak, Simay
dc.contributor.authorKorkmaz Kirakli, Esra
dc.contributor.authorBabalioglu, Ibrahim
dc.contributor.authorErdis, Eda
dc.date.accessioned2024-08-04T20:10:01Z
dc.date.available2024-08-04T20:10:01Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractOBJECTIVE Thymomas, a rare malignancy, are located in 95% anterior mediastinum. They are associated with paraneoplastic syndromes, especially myasthenia graves. Although many classifications are used considering the depth of invasion, presence of metastasis, predominant cell type, or immunohistochemical properties in staging, Masoaka classification is commonly used. Surgery is the most effective method in the treatment of thymoma, and neoadjuvant chemotherapy is recommended in advanced stages (III-IV). Adjuvant radiotherapy has proven efficacy in advanced and inoperable patients. In this study, we aimed to evaluate treatment outcomes and factors affecting prognosis in thymoma patients. METHODS Patients with thymoma who were included in this study voluntarily from seven centers between January 2002 and August 2018 were evaluated retrospectively. RESULTS Of the 158 patients with thymoma, 125 patients with complete data were included in this study. The mean age of the patients was 51.84 (18-84), and 72 were male. Myasthenia graves were present in 64 patients. One hundred thirteen patients were operated and 12 were inoperable. One hundred patients were stage 2, 9 were stage 3, and 16 were stage 4. In our study, 3-year survival was 84.4%, and 5-year survival was 74.9%; inoperable patients, surgical margin positivity, advanced disease and radiotherapy dose less than 50.4'Gy were found to be negative factors affecting survival. In patients with myasthenia graves (MG), survival was higher in patients with stage 2B and less. Survival was lower in epithelial type B3 and type C histologic types. Age, sex, and capsule involvement did not seem to affect survival. CONCLUSION Thymoma is a locally controlled disease with long survival and the results of our study are consistent with the literature. The number of patients should be increased to better define prognostic factors.en_US
dc.identifier.doi10.5505/tjo.2020.2176
dc.identifier.endpage192en_US
dc.identifier.issn1300-7467
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85085896984en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage189en_US
dc.identifier.trdizinid377438en_US
dc.identifier.urihttps://doi.org/10.5505/tjo.2020.2176
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/377438
dc.identifier.urihttps://hdl.handle.net/11616/92560
dc.identifier.volume35en_US
dc.identifier.wosWOS:000537954700010en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofTurk Onkoloji Dergisi-Turkish Journal of Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRadiotherapyen_US
dc.subjectsurgeryen_US
dc.subjectthymomaen_US
dc.titleFactors Affecting Treatment and Prognosis in Thymomas: A Multi-Center Experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu